Abstract: This invention relates in part to soybean event pDAB8264.44.06.1 and includes a novel expression cassettes and transgenic inserts comprising multiple traits conferring resistance to glyphosate, aryloxyalkanoate, and glufosinate herbicides. This invention also relates in part to methods of controlling resistant weeds, plant breeding and herbicide tolerant plants. In some embodiments, the event sequence can be “stacked” with other traits, including, for example, other herbicide tolerance gene(s) and/or insect-inhibitory proteins. This invention further relates in part to endpoint TaqMan PCR assays for the detection of Event pDAB8264.44.06.1 in soybeans and related plant material. Some embodiments can perform high throughput zygosity analysis of plant material and other embodiments can be used to uniquely identify the zygosity of and breed soybean lines comprising the event of the subject invention. Kits and conditions useful in conducting these assays are also provided.

Abstract: A composition for electroless plating comprises: from 9 to 29 weight percent, 9.7 to 29 weight percent, or 10 to 29 weight percent, of a first graft rubber copolymer which comprises the polymerized form of at least one conjugated diene monomer and at least one monovinyl aromatic monomer, from 70 to 90 weight percent, preferably 70-89.7 weight percent, more preferably 70 to 85 weight percent, of ungrafted styrenic polymer, from 0.1 to 10 weight percent of a core/shell diene-based rubber having particle size of 100 to 500 nanometers (nm), one or more of a stabilizer and/or antioxidant in total amount of from 0.1 to 5 weight percent, a fatty acid or a salt of fatty acid in an amount of from 0.1 to 2 weight percent, 0 to 5 weight percent of a mold release agent, 0 to 1 weight percent of a metal oxide, 0 to 3 weight percent of a lubricant, and 0 to 20 weight percent of polycarbonate wherein weight percent and ppm are based on total weight of the composition.

Abstract: This document relates to methods and materials involved in treating cancer. For example, methods and materials for using one or more oncolytic viruses (e.g., one or more replicating oncolytic viruses) to treat cancer in a mammal (e.g., a human) identified as having a cancer likely to respond to oncolytic virotherapy are provided.

Abstract: An emergency lighting system uses a wireless mesh network to control the dimming of luminaires in the event of a power failure or a power outage. Luminaires are commissioned to different dimming power levels depending on localized lighting needs during the power failure of power outage.

Abstract: The present invention in one or more embodiments provides a method of forming an opening on a panel, the method including pressing in a first direction on the panel to form a protrusion with a tip portion, and cutting the protrusion with a force in a second direction to remove the tip portion to form the opening on the panel, the second direction being different from the first direction. The first direction may be a direction of gravity plus and minus up to 15 degrees. The second direction may be transverse to the first direction with an angle differential there-between of 75 to 105 degrees.

Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention provides for anti-Notch3 antibodies, anti-Notch3 antibody-drug conjugates and methods for preparing and using the same.

Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention provides for anti-Notch3 antibodies, anti-Notch3 antibody-drug conjugates and methods for preparing and using the same.

Abstract: The present invention in one or more embodiments provides a method of forming an opening on a panel, the method including pressing in a first direction on the panel to form a protrusion with a tip portion, and cutting the protrusion with a force in a second direction to remove the tip portion to form the opening on the panel, the second direction being different from the first direction. The first direction may be a direction of gravity plus and minus up to 15 degrees. The second direction may be transverse to the first direction with an angle differential there-between of 75 to 105 degrees.

Abstract: The present invention provides for antibodies that bind to Notch1. The present disclosure also provides methods of making the antibodies, pharmaceutical compositions comprising these antibodies and methods of treating disorders with the antibodies and pharmaceutical compositions.

Abstract: The present invention provides for antibodies that bind to Notch1. The present disclosure also provides methods of making the antibodies, pharmaceutical compositions comprising these antibodies and methods of treating disorders with the antibodies and pharmaceutical compositions.

Abstract: Ophthalmic devices suitable for implantation into the eye through small incisions or insertion into an existing orifice are disclosed. These devices are made from a composition comprising crystalline or semi-crystalline polymeric materials which have a glass transition temperature (Tg) of from about ?100° C. to about 37° C., and wherein Tg for the material is lower than Tm for the composition. Disclosed devices include intraocular lenses, corneal inlays, drug delivery devices and implants for reducing intraocular pressure in glaucoma patients.

Abstract: The present invention provides for anti-Notch3 antibodies, anti-Notch3 antibody-drug conjugates and methods for preparing and using the same.

Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention provides for antibodies that bind to Notch1. The present disclosure also provides methods of making the antibodies, pharmaceutical compositions comprising these antibodies and methods of treating disorders with the antibodies and pharmaceutical compositions.

Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.